Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
David Ferreira: Identifying the True Drivers of Recurrent Thrombosis
David Ferreira/LinkedIn
Apr 23, 2026, 08:16

David Ferreira: Identifying the True Drivers of Recurrent Thrombosis

David Ferreira, President of the General Assembly of APIH, shared a post on LinkedIn:

“Therapeutic anti-Xa.

INR on target.

DOAC in the right dose — and taken.

And yet… new thrombosis.

What now?

Increase hypocoagulation?

Change drugs?

Or stop for 30 seconds to think?

There is a pattern that repeats itself — and is rarely questioned: thrombosis patient – correct hypocoagulation – new thrombosis – escalate or change hypocoagulation.

Three very real examples:

  • Sepsis. Activated endothelium, systemic inflammation.
    Will it solve with more hypocoagulation?
  • Lupus Flare/ Immune system in overdrive.
    Will it solve with more hypocoagulation?
  • Catastrophic antiphospholipid syndrome (or similar phenotype). Cascading microthrombosis, consumption.
    Will it solve with more hypocoagulation?

The problem is not hypoglutilation.

It is the reasoning. We increased doses. We changed drugs.

Because these patients are not thrombosing due to ‘lack of anticoagulant.’

They are thrombosing because:

  • Activated endothelium
  • High tissue factor
  • NETs
  • blocked fibrinolysis

In a word – Thrombo-Inflammation!

The system is thus mandatorily programmed to thrombo.

And how do we respond?

More hypocoagulation, hypocoagulant exchange.

This is not therapeutic failure.

It is conceptual failure.

The right question is not ‘What’s the next hypocoagulant?’, but ‘What is fueling this thrombosis?’

And in practice, what changes?

Confirm that you are well hypocoagulated.

Search for the driver.

And then act where it matters:

  • Sepsis/infection – aggressive focus control
  • Active autoimmune disease – immunosuppression (e.g., corticosteroids) plus/minus targeted therapy
  • Severe antiphospholipid syndrome – combined approach (hypocoagulation plus immune modulation depending on context)
  • Active neoplasm – treat the underlying disease
  • Arterial/platelet phenotype – consider antiplatelet therapy (e.g., clopidogrel) in an appropriate context

Hypocoagulation continues.

But it is no longer the center of the strategy.

Because the reality is this:

Hypocoagulation treats the thrombus.

But who decides the outcome… it is inflammation.

If this bothers you, great.

It’s supposed.

At the end of the day, the most important thing about auscultation is not the stethoscope.

It is between the ears of those who wear it.”

David Ferreira: Identifying the True Drivers of Recurrent ThrombosisStay updated with Hemostasis Today.

David Ferreira DOAC Health Hematology Hemostasis News Hemostasis Today Hypocoagulation Medicine thrombosis
NewsFeed